Kytopen and BlueWhale Bio partner for cell therapy innovation
The partnership aims to create a non-viral system to expedite engineered cell therapy delivery by addressing bottlenecks.
Drug Development
Health Canada approves Medison and Ipsen’s Bylvay to treat ALGS
Servier to acquire potential Fragile X syndrome treatment from Kaerus
Epigenic raises $60m for epigenetic treatment development
MD Anderson and Phoenix to advance cell and gene therapy tech
Hengrui Pharma signs deal with Braveheart Bio for HRS-1893
MRM Health gains $64m for microbiome-based biotherapeutic pipeline
Gilead Sciences advances HIV prevention with new US partnership
